Current treatment strategies for age-related ocular conditions

American Journal of Managed Care

Volumn 19, Issue 5 SUPPL., 2013, Pages

  Akpek, Esen K ^a   Smith, Roderick A ^b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; ARTIFICIAL TEAR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BEVACIZUMAB; BIMATOPROST; CARBONATE DEHYDRATASE INHIBITOR; CHOLINERGIC RECEPTOR STIMULATING AGENT; CYCLOSPORIN; DORZOLAMIDE; EYE DROPS; FENOFIBRATE; PROSTAGLANDIN DERIVATIVE; RANIBIZUMAB; SIMVASTATIN; TIMOLOL; TRAVOPROST; VASCULOTROPIN ANTIBODY; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; HYBRID PROTEIN; MONOCLONAL ANTIBODY; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR;

ARTICLE; CENTRAL RETINAL THICKNESS; DIABETIC RETINOPATHY; DRUG EFFICACY; DRUG SAFETY; DRY EYE; GLAUCOMA; GLAUCOMA SURGERY; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INTRAOCULAR PRESSURE; IRIDOTOMY; LASER COAGULATION; LOW LEVEL LASER THERAPY; MEDICATION COMPLIANCE; META ANALYSIS (TOPIC); NEODYMIUM YAG LASER; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN ANGLE GLAUCOMA; OPTIC NERVE LESION; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; PUNCTAL PLUG; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETINA MACULA AGE RELATED DEGENERATION; THERMAL PULSATION SYSTEM; TRABECULAR MESHWORK; TRABECULOPLASTY; VISUAL ACUITY; VISUAL IMPAIRMENT; AGED; ANTAGONISTS AND INHIBITORS; BLOOD; CLINICAL TRIAL (TOPIC); DIABETES MELLITUS; DISEASE COURSE; DRY EYE SYNDROMES; EYE SURGERY; MACULAR DEGENERATION; DRUG ANTAGONISM; RETINA MACULA DEGENERATION; REVIEW;

AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; CLINICAL TRIALS AS TOPIC; CYCLOSPORINE; DIABETES MELLITUS; DIABETIC RETINOPATHY; DISEASE PROGRESSION; DRY EYE SYNDROMES; GLAUCOMA; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; MACULAR DEGENERATION; MEDICATION ADHERENCE; OPHTHALMIC SOLUTIONS; OPHTHALMOLOGIC SURGICAL PROCEDURES; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84894420260     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Jager RD, Mieler WF, Miller JW. Age-related macular degeneration [published correction appears in N Engl J Med. 2008;359(16):1736]. N Engl J Med. 2008;358(24):2606-2617.
2. Meyer CH, Holz FG. Preclinical aspects of anti-VEGF agents for the treatment of wet AMD: ranibizumab and bevacizumab. Eye (Lond). 2011;25(6):661-672.
3. Browning DJ, Kaiser PK, Rosenfeld PJ, Stewart MW. Aflibercept for age-related macular degeneration: a game changer or quiet addition? Am J Ophthalmol. 2012;154(2):222-226.
4. Stewart MW. Aflibercept (VEGF Trap-eye): the newest anti- VEGF drug. Br J Ophthalmol. 2012;96(9):1157-1158.
5. Brown DM, Kaiser PK, Michels M, et al; ANCHOR Study Group. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1432-1444. (Pubitemid 44511558)
6. Rosenfeld PJ, Brown DM, Heier JS, et al; MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1419-1431. (Pubitemid 44511557)
7. FDA News Release. FDA approves new biologic treatment for wet age-related macular degeneration. US Food and Drug Administration website. http://www.fda.gov/newsevents/newsroom/pressannouncements/2006/ucm108685.htm. Accessed April 29, 2013.
8. Shah CP, Garg SJ, Vandar JF, Brown GC, Kaiser RS, Haller JA; Post-Injection Endophthalmitis (PIE) Study Team. Outcomes and risk factors associated with endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents. Ophthalmology. 2011;118(10):2028-2034.
9. Regillo CD, Brown DM, Abraham P, et al. Randomized, doublemasked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am J Ophthalmol. 2008;145(2):239-248.
10. Abraham P, Yue H, Wilson L. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 2. Am J Ophthalmol. 2010;150(3):315-324.e1.
11. Schmidt-Erfurth U, Eldem B, Guymer R, et al; EXCITE Study Group. Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE study. Ophthalmology. 2011;118(5):831-839.
12. Lalwani GA, Rosenfeld PJ, Fung AE, et al. A variable dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO study. Am J Ophthalmol. 2009;148(1):43-58.e1.
13. CATT Research Group; Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011;364(20):1897-1908.
14. Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group; Martin DF, Maguire MG, Fine SL, et al. Ranibizumab and bevacizumab for treatment of neovascular agerelated macular degeneration: two-year results. Ophthalmology. 2012;119(7):1388-1398.
15. Heier JS, Brown DM, Chong V, et al; VIEW 1 and VIEW 2 Study Groups. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012;119(12): 3537-2548.
16. Chang EE, Goldberg JL. Glaucoma 2.0: neuroprotection, neuroregeneration, neuroenhancement. Ophthalmology. 2012;119(5):979-986.
17. Singh K, Sit AJ. Intraocular pressure variability and glaucoma risk. Arch Ophthalmol. 2011;29(8):1080-1081.
18. Caprioli J, Coleman AL. Intraocular pressure fluctuation: a risk factor for visual field progression at low intraocular pressures in the Advanced Glaucoma Intervention Study. Ophthalmology. 2008;115(7):1123-1129.e3.
19. Quigley HA. Glaucoma. Lancet. 2011;377(9774):1367-1377.
20. American Academy of Ophthalmology Glaucoma Panel. Preferred Practice Pattern Guidelines. Primary Open-Angle Glaucoma. San Francisco, CA: American Academy of Ophthalmology; 2010.
21. Collaborative Normal-Tension Glaucoma Study Group. Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Collaborative Normal-Tension Glaucoma Study Group. Am J Ophthalmol. 1998;126(4):487-497.
22. Heijl A, Leske MC, Bengtsson B, Hyman L, Bengtsson B, Hussein M; Early Manifest Glaucoma Trial Group. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol. 2002;120(10):1268-1279. (Pubitemid 36105431)
23. Lichter PR, Musch DC, Gillespie BW, et al; CIGTS Study Group. Interim clinical outcomes in the Collaborative Initial Glaucoma Treatment Study comparing initial treatment randomized to medications or surgery. Ophthalmology. 2001;108(11):1943-1953.
24. Stewart WC, Konstas AG, Nelson LA, Kruft B. Meta-analysis of 24-hour intraocular pressure studies evaluating the efficacy of glaucoma medications. Ophthalmology. 2008;115(7):1117-1122.e1.
25. Okeke CO, Quigley HA, Jampel HD, et al. Interventions improve poor adherence with once daily glaucoma medications in electronically monitored patients. Ophthalmology. 2009;116(12): 2286-2293.
26. Friedman DS, Quigley HA, Gelb L, et al. Using pharmacy claims data to study adherence to glaucoma medications: methodology and findings of the Glaucoma Adherence and Persistence Study (GAPS). Invest Ophthalmol Vis Sci. 2007;48(11):5052-5057. (Pubitemid 351260915)
27. Boland MV, Ervin AM, Friedman D, et al. Treatment for Glaucoma: Comparative Effectiveness. Comparative Effectiveness Review No. 60. (Prepared by the Johns Hopkins University Evidence-based Practice Center under Contract No. HHSA 290- 2007-10061-I.) AHRQ Publication No. 12-EHC038-EF. Rockville, MD: Agency for Healthcare Research and Quality; April 2012.
28. Gedde SJ, Schiffman JC, Feuer WJ, Herndon LW, Brandt JD, Budenz DL; Tube Versus Trabeculectomy Study Group. Three-year follow up of the tube versus trabulectomy study. Am J Ophthalmol. 2009;148(5):670-684.
29. Nguyen QD, Brown DM, Marcus DM, et al; RISE and RIDE Research Group. Ranibizumab for diabetic macular edema: results from two phase III randomized trials: RISE and RIDE. Ophthalmology. 2012;119(4):789-801.
30. FDA approves Lucentis to treat diabetic macular edema [press release]. US Food and Drug Administration website. http://www.fda.gov/NewsEvents/Newsroom/ PressAnnouncements/ucm315130.htm. Accessed April 29, 2013.
31. Do DV, Nguyen QD, Boyer D, et al; DA VINCI Study Group. One-year outcomes of the DA VINCI Study of VEGF Trap-Eye in eyes with diabetic macular edema. Ophthalmology. 2012;119(8):1658-1665.
32. The ACCORD Study Group; ACCORD Eye Study Group; Chew EY, Ambrosius WT, Davis MD, et al. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med. 2010; 363(3):233-244.
33. American Academy of Ophthalmology Cornea/External Disease Panel. Preferred Practice Pattern Guidelines. Dry Eye Syndrome - Limited Revision. San Francisco, CA: American Academy of Ophthalmology; 2011.
34. Behrens A, Doyle JJ, Stern L, et al; Dysfunctional Tear Syndrome Study Group. Dysfunctional tear syndrome: a Delphi approach to treatment recommendations. Cornea. 2006;25(8):900-907. (Pubitemid 44763848)
35. Akpek EK, Klimava A, Thorne JE, Martin D, Lekhanont K, Ostrovsky A. Evaluation of patients with dry eye for presence of underlying Sjögren syndrome. Cornea. 2009;28(5):493-497.
36. Sall K, Stevenson OD, Mundorf TK, Reis BL. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. Ophthalmology. 2000;107(4):631-639. (Pubitemid 30191329)
37. Perry HD, Solomon R, Donnenfeld ED, et al. Evaluation of topical cyclosporine for the treatment of dry eye disease. Arch Ophthalmol. 2008;126(8):1046-1050.
38. Roberts CW, Carniglia PE, Brazzo BG. Comparison of topical cyclosporine, punctal occlusion, and a combination for the treatment of dry eye. Cornea. 2007;26(7):805-809. (Pubitemid 47220551)
39. News. TearScience Achieves FDA Clearance for Second Generation LipiFlow Thermal Pulsation System. TearScience website. http://www.tearscience.com/en/ tearscience-achieves-fda-clearance-for-second-generation-lipiflow-thermal- pulsation-system. Accessed April 29, 2013.
40. Lane SS, DuBiner HB, Epstein RJ, et al. A new system, the LipiFlow, for the treatment of meibomian gland dysfunction. Cornea. 2012;31(4):396-404.
41. Maskin SL. Intraductal meibomian gland probing relieves symptoms of obstructive meibomian gland dysfunction. Cornea. 2010;29(10):1145-1152.